SCHEMBL376732

SCHEMBL376732

CC1(C)CCN(c2ccc(C(N)=NS(=O)(=O)c3ccc(F)c([N+](=O)[O-])c3)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 10/20 0.44
BCL2L1 Q07817 10/20 0.44
LMNA P02545 4/20 0.43
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 3/20 0.41
MITF O75030 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 3/20 0.40
MAPK1 P28482 3/20 0.40
KMT2A Q03164 3/20 0.40
VCAM1 P19320 1/20 0.40
ALB P02768 1/20 0.40
BCL2L2 Q92843 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13503899 1.00 BCL2 (0.44) BCL2BCL2L1LMNAALDH1A1SMN1; SMN2
SCHEMBL13503636 0.84 BCL2L1 (0.44) BCL2BCL2L1LMNAMAPT
SCHEMBL3589188 0.84 BCL2L1 (0.44) BCL2BCL2L1LMNAMAPT
SCHEMBL13503905 0.83 BCL2L1 (0.49) BCL2BCL2L1
SCHEMBL376472 0.83 BCL2L1 (0.49) BCL2BCL2L1
SCHEMBL13503581 0.83 BCL2L1 (0.52) BCL2BCL2L1
SCHEMBL376748 0.83 BCL2L1 (0.52) BCL2BCL2L1
SCHEMBL376938 0.82 BCL2L1 (0.48) BCL2BCL2L1LMNAALDH1A1MAPT
SCHEMBL13503522 0.82 BCL2L1 (0.48) BCL2BCL2L1LMNAALDH1A1MAPT
SCHEMBL13503583 0.81 BCL2L1 (0.50) BCL2BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD BCL2 2/4885BCL2L1 18/4885LMNA 141/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD BCL2 2/4885BCL2L1 18/4885LMNA 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.